# Assumption Review — WHY1
**Agent**: SAGE | **Mode**: assumption-challenge | **Date**: 2026-04-03
**Run**: squad-1775169176 | **Spec**: 017 (NS-003 Prototype + U-CA-004 Experiment)

---

## Verdict: FAIL

**FAIL reason:** Three CRITICAL issues cannot be resolved by autonomous interpretation alone. Two require human input (IS-001, IS-003), and one exposes a logical contradiction with constitutional text that no agent has authority to resolve (IS-002). Until these are resolved, the WHAT phase cannot begin on a valid foundation.

---

## Summary

SYNTHESIZER produced a competent synthesis. The FPCR threshold resolution (0.80 authoritative) is defensible but remains advisory — the human brief said 0.70 and the autonomous override is not a constitutional amendment. The write-time hook gap (GAP-001 / U-009) is far more severe than SYNTHESIZER characterized: the ns003-experiment-design.md does NOT specify an interception mechanism at COMMANDER level — it specifies a Critic function that is "called by COMMANDER post-agent-LLM-call, pre-artifact-commit," but this is a requirements assumption masquerading as an architectural fact. The endocrine Phase 1 state (confirmed in state.json) means Phase 3 event hooks are present in endocrine.sh but NOT actively wired in the current COMMANDER dispatch protocol, contradicting A-006 which asserts they are validated. Most critically: the P-006 authorization lives only in state.json and was never processed through `/speckit.constitution`, creating a governance gap that would invalidate any implementation work done under that authorization if challenged.

---

## Assumption Analysis

### A-001: NS-003 Critic is a deterministic Python validator [PASS — validated]

**Evidence basis:** Strong. Stated in glossary.md (spec 015), ns003-experiment-design.md Section 7, and multiple artifact cross-references.

**Logical consistency:** Consistent with A-002 (SDK for Generator only) and A-009 (Markdown parsing layer needed).

**Challenge:** SYNTHESIZER correctly validated this. No challenge survives. The distinction between deterministic Critic and LLM Generator is load-bearing for the novelty claim (no NL2GenSym conflation) and is consistently stated. PASS.

**Criticality if wrong:** Patent collapse. But evidence is strong enough that this is the right bet.

---

### A-002: Anthropic SDK is accessible via Python [MEDIUM — unvalidated, correctly flagged]

**Evidence basis:** Weak — zero Python scripts import `anthropic`. Inference only from token-logger.py's anticipatory field names.

**Logical consistency:** Consistent with the overall architecture, but consistency does not equal feasibility.

**Challenge — deepened:** SYNTHESIZER notes this as unvalidated but does not probe the deeper issue: the extension framework may not support long-running Python subprocesses that maintain an SDK connection across 30 agent invocations. The speckit CLI runs agents as subagents via `claude -p`. If NS-003 wraps those invocations, the Python SDK must be callable from within the subagent context — which means the ANTHROPIC_API_KEY must be available in the subagent's environment, not just the parent shell. This environment inheritance is not confirmed.

**New specific unknown:** Does ANTHROPIC_API_KEY propagate into the subagent environment when speckit dispatches via `claude -p`? If not, the SDK cannot authenticate. This is a must-resolve before HOW.

**Severity:** HIGH (measurement fidelity at risk; experiment reproducibility at risk).

---

### A-003: Schema formalization for 6 artifact types is feasible [HIGH — unvalidated, understated risk]

**Evidence basis:** Weak (ARTIFACT_STAGE_MAP exists, but existence of a taxonomy ≠ schemas can be written without false rejections).

**Challenge — deepened:** The ns003-experiment-design.md Section 7 Phase 1 completion criterion requires "zero false rejections on known-good samples from prior runs 008-014." Runs 008-014 are NOT confirmed accessible (GAP-004). This creates a circular dependency: schema feasibility cannot be validated without known-good samples, and the Phase 1 completion criterion depends on schema feasibility being proved against those samples. SYNTHESIZER acknowledges GAP-004 as HIGH risk but does not flag the circular dependency: if runs 008-014 are unavailable AND the fallback is "use runs 015-016 or synthetic samples," the pre-registered Phase 1 criterion is silently modified without formal documentation. This is a reproducibility violation under Section 8.

**Additional challenge:** The FPCR number will conflate schema coverage gaps with agent compliance gaps (SUSP-001 from contradictions-and-gaps.md). This is not a suspicion — it is a structural certainty. JSON Schema cannot validate unstructured prose. If prose content > 40% of any artifact type (highly likely for DISCOVER and WHY agents), FPCR on those agents is structurally misleading. This is a metric validity problem that should be labeled CRITICAL, not MEDIUM (RSK-010 is underclassified).

**Revised severity:** CRITICAL on the metric validity axis (not just HIGH). Recommend: SCIENTIST must measure structured-to-prose ratio on runs 015-016 BEFORE Phase 1 schema design begins.

---

### A-004: FPCR threshold — CRIT-001 [CRITICAL — CHALLENGED, AUTONOMOUS RESOLUTION INSUFFICIENT]

**SYNTHESIZER resolution:** Pre-registered 0.80 is authoritative; 0.70 is minimum viable start threshold.

**Challenge:**

**Challenge 1 — The autonomous resolution violates its own stated authority.** SYNTHESIZER's resolution is documented in user-intent.md and the reasoning journal. However, the human brief says 0.70. The constitution (P-001 through P-019) grants no agent authority to override a human-stated requirement. The pre-registration principle (ns003-experiment-design.md Section 8) is a constraint on verdict reporting, not on implementation targets. Using 0.80 as the authoritative PASS criterion when the brief said 0.70 is not "the conservative interpretation" — it is a direct override of the human's stated target. The fact that pre-registration science supports 0.80 does not grant SYNTHESIZER authority to reinterpret what the human meant.

**Challenge 2 — The interpretation creates an undisclosed experiment failure mode.** Under the SYNTHESIZER resolution: if FPCR = 0.73 (which would be "success" per the brief), the experiment verdict is INCONCLUSIVE. The human may not be aware that their target of 0.70 is formally INCONCLUSIVE under the pre-registered design. This undisclosed failure mode should have been surfaced as an escalation item, not resolved autonomously.

**Challenge 3 — The pre-registered criterion was written by ARCHITECT in spec 015, not the human.** The ns003-experiment-design.md was produced by ARCHITECT (HOW) in run squad-1775154996. The human brief was the human's own statement. When two non-human sources conflict, autonomous resolution by SYNTHESIZER choosing one over the other is a routing violation (P-003: COMMANDER routes, agents do not self-route). SYNTHESIZER should have escalated to COMMANDER, not resolved it.

**Required action:** Human must confirm: (a) Is 0.70 the intended PASS criterion or an exploration threshold? (b) If 0.70 was the intent, does the human want to formally amend the pre-registered threshold with a documented rationale (which would appear in the experiment report)?

**Severity:** CRITICAL — IS-001.

---

### A-005: U-CA-004 runs on the Echelon extension codebase [MEDIUM — correctly flagged]

**Evidence basis:** Moderate. Spec 014 analysis documented the codebase. Accessibility at experiment time is not confirmed.

**Challenge:** The ns003-experiment-design.md Section 8 specifies the test codebase path as an absolute path on a specific machine: `/Users/ladislavbihari/myWork/competition/.specify/extensions/echelon/`. This is a reproducibility violation by design — any third party would not have this path. The document acknowledges this ("Alternative: any single well-understood Java or Python monorepo") but does not specify a commit hash. A reproducible experiment requires a commit hash, not a local path. This should be flagged as a gap in the experiment design itself, not merely a risk.

**Additional challenge:** The spec 015 experiment design and the spec 017 implementation plan both assume the test codebase is at the path above. If the echelon extension has been updated since spec 014 analyzed it (42 agents, 7 tiers), the ISS-001 failure mode baseline and the AQS scoring calibration (U-CA-004) are both stale. A commit hash lock is not just good practice — it is required by the reproducibility principle.

**Severity:** HIGH — add to IS as a requirement gap (missing commit hash lock as mandatory deliverable).

---

### A-006: endocrine.sh Phase 3 provides all hooks needed for NS-003 and CA overlay wiring [CRITICAL — CHALLENGED, MISCLASSIFIED AS VALIDATED]

**SYNTHESIZER/SCOUT assessment:** [validated] — "All required hooks exist in Phase 3 command set."

**Challenge:**

**Challenge 1 — "Hooks exist" ≠ "Hooks are wired."** The endocrine.sh commands `on_gate_pass`, `on_gate_fail`, `on_quality_improvement` etc. exist in the file (confirmed at lines 654-736). The Phase 3 commands exist (lines 686-810). But the COMMANDER dispatch protocol (commander.md sections 208-234) only implements Phase 1: adrenaline and decay. The post-dispatch protocol reads verbatim: "Apply decay: Run `scripts/bash/endocrine.sh decay_hormones <agent>`." There is NO call to `on_gate_pass`, `on_gate_fail`, or `on_quality_improvement` anywhere in the post-dispatch protocol. These Phase 3 commands exist in endocrine.sh but are not called from COMMANDER. Furthermore, state.json confirms `endocrine_phase: 1` — Phase 3 is not active in the current run.

**Challenge 2 — Adding Phase 3 wiring requires COMMANDER.md changes.** The assumption that "wiring is purely at COMMANDER.md level" is correct. But the assumption that this is a small change is not. COMMANDER.md must be extended to: (a) call `on_gate_pass` / `on_gate_fail` after each agent dispatch, (b) detect NS-003 ConflictSignal outcomes and call the appropriate event, (c) handle the new post-dispatch, pre-commit NS-003 hook (GAP-001). This is three separate new protocol sections, not a minor addition.

**Challenge 3 — CA overlay integration requires more than endocrine wiring.** For Goal Stack overlay, u-ca-004-experiment-spec.md Section 8 explicitly states it "requires COMMANDER modification (replacing sequential dispatch with precondition-checking loop)." For LIDA Broadcast, it requires "concurrent agent invocation and NS-003 Critic serialization (race condition handling)." These are not endocrine.sh hook additions — they are fundamental changes to the COMMANDER dispatch architecture. SCOUT's assertion that "endocrine.sh Phase 3 already provides all hooks needed" is correct only for the NS-003 event wiring. It is incorrect for the CA overlay integration more broadly. This conflation led to A-006 being marked [validated] when it should be [partially validated — hooks exist, wiring and overlay integration are NOT validated].

**Revised status:** [partially validated — misclassified]. The endocrine.sh Phase 3 commands exist, but (a) they are not called from COMMANDER in any current code, (b) Phase 3 is not active in the current squad run, and (c) CA overlay integration for overlays beyond ACT-R requires COMMANDER architecture changes that go beyond endocrine hook calls.

**Severity:** CRITICAL for the assumption status misclassification — A-006 should not be [validated]. IS-002.

---

### A-007: scipy installable [PASS — low-risk, correctly assessed]

**Challenge:** Standard scientific Python stack. pip install scipy works in any Python 3.8+ environment with pip. The dependency management gap (GAP-002) is the real risk, not scipy availability. PASS.

---

### A-008: ACT-R test order maintained [PASS — validated, correctly assessed]

**Challenge:** Pre-registered in experiment spec. Not an architectural assumption. PASS.

---

### A-009: JSON Schema validation requires Markdown → dict parsing [PASS — validated]

**Challenge:** contradiction-scanner.py demonstrates feasibility. The stop-key list is calibration data. PASS on the feasibility claim. (The metric validity concern — prose coverage — is tracked under A-003 challenge.)

---

### A-010: Sample sizes fixed [PASS — validated]

**Challenge:** Stated in ns003-experiment-design.md Section 8 reproducibility requirement. PASS.

---

## Critical Item Challenges (SYNTHESIZER-Flagged)

### CRIT-001 / A-004: FPCR Threshold — See A-004 analysis above
**Verdict:** SYNTHESIZER's autonomous resolution is challenged as exceeding agent authority. Human confirmation required. IS-001.

---

### GAP-001 / U-009: Write-Time Interception Hook in COMMANDER [CRITICAL — DEEPENED]

**Challenge — Architecture feasibility challenge for A-001:**

The SYNTHESIZER correctly elevated this to the highest-priority architectural gap. But the challenge goes further than flagged.

**The ns003-experiment-design.md does NOT specify a write-time interception mechanism.** Section 7 Phase 2 states the Critic is "called by COMMANDER post-agent-LLM-call, pre-artifact-commit" — but this is a requirements statement about WHERE it should be called, not evidence that the hook EXISTS. The ARCHITECT (HOW) wrote this as a design requirement, not as a description of existing capability.

**The actual interception architecture has two mutually incompatible models, and neither is proven feasible:**

**Model A (post-dispatch):** COMMANDER dispatches the agent as a subagent via `claude -p`, captures the LLM output as a string before writing it to a file, runs the Critic on the string, then writes the file (or retries). This requires COMMANDER to control the file write step — meaning agents must NOT write their own files via Write tool calls inside their LLM context. If agents self-write (which is the current pattern — agents use Write tool calls to produce their artifacts), COMMANDER has no interception point.

**Model B (write-wrapper utility):** All agents call a write utility function rather than writing directly. The write utility calls the Critic before each write. This requires modifying every agent's prompt to use the utility, not the Write tool. This is a systemic change to the agent protocol, not a COMMANDER addition.

**The critical question:** Do current Echelon agents write their own artifact files via Write tool calls inside their own LLM context? If yes, Model A is infeasible. If COMMANDER receives the output as a return value and THEN writes the file, Model A is feasible.

**This is NOT currently answered.** SCOUT flagged it (RJ-009). SYNTHESIZER elevated it. But no one has checked whether the actual squad.run.md or squad.build.md commands describe the artifact write mechanism.

**Resolution:** Check `commands/squad.run.md` and `commands/squad.build.md` to determine the artifact write mechanism. If agents self-write, NS-003-A must degrade to post-hoc (eliminating the pre-commit novelty claim). If COMMANDER writes, NS-003 is feasible as designed.

**Patent validity risk:** If Model A is infeasible and Model B is the only option, the patent claims for NS-003-B's "pre-commit" architecture depend on a modified agent protocol that does not exist yet. The novelty claim ("pre-commit, not post-hoc") cannot be established until the write mechanism is determined.

**Severity:** CRITICAL — IS-003.

---

### P-006 Authorization: Governance Adequacy [CRITICAL — IS-002]

**SYNTHESIZER assessment:** "P-006 authorization confirmed in state.json human_override.p006_ca_overlays = AUTHORIZED."

**Challenge:**

**Challenge 1 — state.json authorization is informal.** P-006 in the constitution reads: "The five CA overlays are GATE_BLOCKED. No implementation code may be written for these mechanisms until U-CA-004 resolves POSITIVE. This gate is absolute." The constitution (section header) states: "Only the human may amend this constitution via `/speckit.constitution`. Agents may APPEND technical sub-principles... but may NEVER modify human-defined principles." P-006 is a HUMAN-DEFINED principle. Bypassing it requires a formal amendment via `/speckit.constitution`, not a state.json field.

**Challenge 2 — The authorization scope is inconsistent with the gate.** The user-intent.md documents the human authorization as covering "NS-003 prototype build AND U-CA-004 experiment infrastructure AND conditional CA overlay implementation artifacts." But P-006 gates CA overlay IMPLEMENTATION CODE, not experiment infrastructure. The U-CA-004 experiment itself (running the 60 invocations, building the ACT-R preprocessing function for Condition C) is not prohibited by P-006 — it is exactly the mechanism by which P-006's gate condition ("U-CA-004 resolves POSITIVE") is evaluated. However, "conditional CA overlay implementation artifacts" is ambiguous: if it means "write implementation code for the CA overlays conditionally once U-CA-004 resolves POSITIVE," that is fine. If it means "write implementation code for CA overlays now, in advance," that violates P-006.

**Challenge 3 — BANZAI mode does not override constitutional gates.** The constitution is described as "immutable except by human amendment." BANZAI mode grants autonomous decision-making within constitutional bounds — it does not grant authority to bypass HUMAN-DEFINED principles without a constitutional amendment. The state.json entry (`human_override`) is an agent-writable field, not a constitutional amendment. An agent (even COMMANDER) updating state.json does not constitute a constitutional change.

**Required action:** The human must formally amend P-006 via `/speckit.constitution` to reflect the authorization, or the authorization must be scoped to permit only: (a) building U-CA-004 experiment infrastructure (permitted — not prohibited by P-006), (b) building NS-003 prototype (permitted — not blocked by P-006), and (c) building the ACT-R preprocessing function used in U-CA-004 Condition C (borderline — it is part of the experiment, not production overlay). "Implementation code for CA overlays" must NOT be written until U-CA-004 resolves POSITIVE, regardless of the state.json entry.

**Severity:** CRITICAL — IS-002.

---

### U-CA-004 Experimental Validity: N=20 Real vs Simulated Runs [CRITICAL — IS-004]

**SYNTHESIZER assessment:** Not directly addressed. SCOUT did not flag this.

**Challenge:**

**Challenge 1 — Real runs or simulated?** The U-CA-004 experiment requires 60 actual Echelon agent invocations (20 per condition) on the test codebase. These are not simulations — each invocation calls the Claude API (consuming tokens), generates an artifact, and is scored by an evaluator. At current API costs, 60 full Echelon pipeline runs could cost hundreds of dollars. The experiment spec does not address cost or confirm that this level of API usage is authorized.

**Challenge 2 — AQS rubric requires human evaluators.** u-ca-004-experiment-spec.md Section 6 defines AQS scoring as requiring an evaluator to assess four dimensions (Completeness, Precision, Internal Consistency, Scope Compliance) using 0-3 anchors per dimension, with access to the agent's prompt definition, all prior stage artifacts from the same run, and the test codebase itself. The experiment spec states "Where only one evaluator is available, this limitation is stated in the experiment report." This is not AQS automation — it is human scoring. The experiment cannot be run autonomously (BANZAI mode) if AQS scoring requires human evaluation. An automated AQS proxy would need to be defined and pre-registered, but no such proxy exists in the experiment spec.

**Challenge 3 — Single evaluator = evaluator IS the human.** In BANZAI mode ("no human in loop"), there are no human evaluators available. The AQS score is the primary dependent variable in U-CA-004. Without human evaluators, the U-CA-004 experiment cannot be executed as specified. The entire experimental validity depends on AQS scores that require human judgment.

**This is a BANZAI mode incompatibility:** U-CA-004 as designed CANNOT be run in BANZAI mode (no human in loop) because AQS scoring is not automatable from the experiment spec as written. Either (a) an automated AQS proxy must be defined and its correlation with human AQS validated before the experiment, or (b) the human must confirm they will serve as evaluator post-experiment (BANZAI mode for execution, human evaluation for scoring), or (c) the experiment design is invalid for autonomous execution.

**Severity:** CRITICAL — IS-004. This is a blocking incompatibility between BANZAI mode and the U-CA-004 experimental protocol.

---

### CA Overlay Integration: endocrine.sh Phase 3 Hook Sufficiency [CRITICAL — IS-002 component]

See A-006 challenge above. The key finding: "endocrine.sh Phase 3 provides all hooks needed" is factually incorrect as applied to the broader CA overlay integration claim. The hooks exist in the script but are not wired in COMMANDER. Goal Stack and LIDA Broadcast require COMMANDER architecture changes beyond hook wiring. This is a HIGH misclassification in assumptions.md that has propagated into the project's false sense of confidence about integration complexity.

---

## Domain Model Consistency Check

### Glossary Completeness

Terms used in mental-model.md and boundaries.md that require disambiguation:

1. **"write-time" vs "pre-commit":** Used interchangeably across artifacts. The boundaries.md describes the Critic as called "post-agent-LLM-call, pre-artifact-commit." But "pre-commit" in the NS-003 novelty claim (RJ-004) means "before the artifact file is written." If agents write their own files (the likely current mechanism), there is NO COMMANDER-level pre-commit point — the "pre-commit" claim is a design aspiration, not an existing capability. The glossary should distinguish: "pre-commit (design goal — Critic fires before Write tool)" vs "post-hoc (current baseline — contradiction-scanner.py fires after all artifacts written)."

2. **"BANZAI mode":** Used in state.json and user-intent.md but not defined in the glossary. Agents are operating under this mode without a formal definition of its authority scope relative to the constitution.

3. **"Phase 3 active":** The glossary and mental-model reference endocrine Phase 3 events. state.json shows `endocrine_phase: 1`. The artifacts assert Phase 3 hook availability but the current run state contradicts Phase 3 being active. This ambiguity is load-bearing for A-006.

### Circular Dependency Check

**Circular dependency identified:** Schema calibration (Phase 1, NS-003) requires known-good samples from runs 008-014 (GAP-004) → runs 008-014 require the test codebase to be at a fixed commit hash (A-005) → commit hash lock requires both NS-003 and U-CA-004 to use the same hash → U-CA-004 experiment requires the same codebase that NS-003 calibrated on → NS-003 calibration requires runs 008-014, which may not exist in accessible form. The fallback (synthetic samples) breaks the pre-registered Phase 1 completion criterion.

This is not a fatal cycle, but it is a requirements contradiction that must be resolved before Phase 1 begins.

### LOC Claim Audit

No LOC claims found in staging artifacts. No flag required.

### Resolution Evidence Check

**SYNTHESIZER's resolution of CRIT-001:** Resolved by asserting "pre-registered 0.80 is authoritative." Resolution evidence: SYNTHESIZER reasoning in user-intent.md. No integration protocol, no code example, no failure mode analysis. **Flag: name-only resolution.** The resolution asserts a threshold without a mechanism for how the implementation will target 0.80 vs 0.70. IS-001.

---

## Pre-Mortem: Where Is Our Understanding Most Likely Wrong?

### Most dangerous misrepresentation: The "pre-commit" novelty claim
If Echelon agents write their own artifact files via Write tool calls inside their LLM context (the standard pattern for subagents), COMMANDER has no interception point. The entire "pre-commit" architecture collapses to "we added a validation wrapper utility that agents must call instead of Write." This is a protocol change, not a COMMANDER integration. It is still technically achievable, but it is not what the ns003-experiment-design.md describes, and it requires updating every agent's instructions. The novelty claim survives (it is still pre-write, not post-hoc), but the implementation complexity is 5-10x higher than assumed.

### Most likely wrong boundary: endocrine Phase 3 wiring scope
DISCOVER said "wiring is purely at COMMANDER.md level — no endocrine.sh changes needed." This is likely wrong for CA overlays beyond ACT-R. Goal Stack dispatch architecture changes require significant COMMANDER.md restructuring that is beyond simple hook additions.

### Most likely incorrect cardinality: N=20 per condition assumes one evaluator
The experiment spec acknowledges the single-evaluator limitation but does not address the BANZAI mode incompatibility. In practice, there will be zero human evaluators available during the autonomous run. The AQS scores will either not exist or require post-hoc human review — making the "automated experiment execution" a partial automation at best.

### Most likely false assumption: runs 008-014 are accessible
The `.specify/specs/` directory shows only 015 and 016. Runs 008-014 are either not archived, on a different machine, or did not exist in the expected form. The Phase 1 completion criterion depends on them. High probability of fallback to synthetic samples, which modifies the pre-registered criterion.

### Most dangerous external dependency behavior: Claude API model version lock
The experiment requires all 60 runs to use the same model API string. If the model version changes mid-experiment (Anthropic releases an update), the entire batch must restart. The experiment spec acknowledges this but does not specify how to detect a mid-batch model version change. If the runner script does not check the API model string per invocation, a mid-batch update is undetectable.

---

## Unknowns Prioritization for SCIENTIST

| Unknown | Priority | Recommended Resolver | Rationale |
|---------|----------|---------------------|-----------|
| U-009: Write-time interception mechanism (audit squad.run.md) | P1 — blocks all NS-003 design | [domain-expert] audit commands/squad.run.md | Determines architectural feasibility |
| U-001: FPCR threshold (human confirmation) | P1 — blocks experiment verdict validity | [user] | Cannot proceed without this |
| AQS automation feasibility (NEW — IS-004) | P1 — blocks BANZAI mode execution of U-CA-004 | [user] | BANZAI mode incompatibility |
| P-006 formal amendment | P1 — governance | [user] via /speckit.constitution | Constitutional integrity |
| U-007: Runs 008-014 location | P1 — blocks Phase 1 calibration | [user] | Phase 1 gate |
| U-002: SDK vs CLI invocation pattern | P2 | [domain-expert] inspect extension.yml | Token fidelity |
| SUSP-001: Structured-to-prose ratio | P2 | SCIENTIST — measure on runs 015-016 | FPCR validity |
| SUSP-002: Evaluator blinding feasibility | P3 (deferred — IS-004 supersedes) | SCIENTIST | Only relevant if AQS can be automated |

---

## Pass/Fail Assessment

| Criterion | Status |
|-----------|--------|
| All CRITICAL assumptions validated or investigation-planned | FAIL — A-006 misclassified as [validated]; A-004 resolved without authority |
| No logical contradictions between artifacts | FAIL — endocrine_phase:1 in state.json vs Phase 3 described as active |
| Glossary terms disambiguated | PARTIAL — "write-time/pre-commit," "BANZAI mode," "Phase 3 active" are ambiguous |
| Unknowns cataloged with priorities and resolvers | PASS — SYNTHESIZER unknowns.md is thorough |
| No HIGH-severity issues unaddressed | FAIL — IS-002 (P-006 governance), IS-003 (write-time hook), IS-004 (AQS/BANZAI incompatibility) are new CRITICAL issues |

**Overall Verdict: FAIL — 3 of 5 criteria fail.**

**Blocking items before WHAT phase:**
1. IS-001: Human must confirm FPCR threshold (0.70 or 0.80)
2. IS-002: P-006 must be formally amended via `/speckit.constitution` or authorization scope must be clarified
3. IS-003: Artifact write mechanism must be audited before NS-003 architecture is designed
4. IS-004: AQS automation must be resolved or U-CA-004 experimental protocol must be revised for BANZAI mode

---

*SAGE — adversarial review complete. Findings are reported as issues, not prescriptions. COMMANDER routes resolution.*
